Michael J. Tomsicek
2017 - CRISPR Therapeutics AG
In 2017, Michael J. Tomsicek earned a total compensation of $2.2M as Chief Financial Officer at CRISPR Therapeutics AG.
Compensation breakdown
| Bonus | $50,000 |
|---|---|
| Non-Equity Incentive Plan | $23,987 |
| Option Awards | $2,035,542 |
| Salary | $51,885 |
| Total | $2,161,414 |
Tomsicek received $2M in option awards, accounting for 94% of the total pay in 2017.
Tomsicek also received $50K in bonus, $24K in non-equity incentive plan and $51.9K in salary.
Rankings
In 2017, Michael J. Tomsicek's compensation ranked 5,142nd out of 14,666 executives tracked by ExecPay. In other words, Tomsicek earned more than 64.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,142 out of 14,666 | 65th |
Division Manufacturing | 1,830 out of 5,768 | 68th |
Major group Chemicals And Allied Products | 545 out of 2,074 | 74th |
Industry group Drugs | 420 out of 1,730 | 76th |
Industry Biological Products, Except Diagnostic Substances | 78 out of 316 | 75th |
Source: SEC filing on April 30, 2019.
Tomsicek's colleagues
We found four more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2017.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019
ABIOMED CEO Michael Minogue's 2018 pay slips 16% to $10M
June 22, 2018